| Correction to Lancet Respir Med 2020; 8: 786–94 | Lancet Respiratory Medicine | 1 day | save |  |  |  |  |
| Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials | Lancet Respiratory Medicine | 2 days | save | | | | |
| Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform | Lancet Respiratory Medicine | 2 days | save | | | | |
| Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? | Lancet Respiratory Medicine | 2 days | save | | | | |
| Human recombinant soluble ACE2 in severe COVID-19 | Lancet Respiratory Medicine | 2 days | save | | | | |
| Hard to reach: COVID-19 responses and the complexities of homelessness | Lancet Respiratory Medicine | 3 days | save | | | | |
| COVID-19 among people experiencing homelessness in England: a modelling study | Lancet Respiratory Medicine | 3 days | save | | | | |
| COVID-19 testing in the UK | Lancet Respiratory Medicine | 4 days | save | | | | |
| Pooled saliva samples for COVID-19 surveillance programme | Lancet Respiratory Medicine | 4 days | save | | | | |
| National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study | Lancet Respiratory Medicine | 4 days | save | | | | |
| Amazon fires coincide with increased respiratory illnesses in indigenous populations | Lancet Respiratory Medicine | 4 days | save | | | | |
| The UCL Ventura CPAP device for COVID-19 | Lancet Respiratory Medicine | 4 days | save | | | | |
| 2020 European Respiratory Society International Virtual Congress | Lancet Respiratory Medicine | 8 days | save | | | | |
| Aspirin for the primary prevention of sepsis | Lancet Respiratory Medicine | 9 days | save | | | | |
| Effect of aspirin on deaths associated with sepsis in healthy older people (ANTISEPSIS): a randomised, double-blind, placebo-controlled primary prevention trial | Lancet Respiratory Medicine | 9 days | save | | | | |
| Serological assays for delayed SARS-CoV-2 case identification | Lancet Respiratory Medicine | 12 days | save | | | | |
| Serological assays for delayed SARS-CoV-2 case identification – Author's reply | Lancet Respiratory Medicine | 12 days | save | | | | |
| More options for managing severe asthma in adults | Lancet Respiratory Medicine | 17 days | save | | | | |
| Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial | Lancet Respiratory Medicine | 17 days | save | | | | |
| Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial | Lancet Respiratory Medicine | 18 days | save | | | | |
| Advances in understanding and reducing the burden of severe asthma in children | Lancet Respiratory Medicine | 19 days | save | | | | |
| Reducing the burden of asthma: time to set research and clinical priorities | Lancet Respiratory Medicine | 19 days | save | | | | |
| Mariëlle Pijnenburg: solving the puzzle of asthma | Lancet Respiratory Medicine | 19 days | save | | | | |
| The genetics of asthma and the promise of genomics-guided drug target discovery | Lancet Respiratory Medicine | 19 days | save | | | | |
| COVID-19 vaccine trials in Africa | Lancet Respiratory Medicine | 21 days | save | | | | |
| The Russian vaccine for COVID-19 | Lancet Respiratory Medicine | 21 days | save | | | | |
| IASLC 2020 World Conference on Lung Cancer | Lancet Respiratory Medicine | 29 days | save | | | | |
| Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Respiratory Medicine | 29 days | save | | | | |
| Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study | Lancet Respiratory Medicine | 30 days | save | | | | |
| Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study | Lancet Respiratory Medicine | 30 days | save | | | | |
| Physiological and biological heterogeneity in COVID-19-associated acute respiratory distress syndrome | Lancet Respiratory Medicine | 30 days | save | | | | |
| Pharmacotherapy for pulmonary arterial hypertension | Lancet Respiratory Medicine | 32 days | save | | | | |
| When to consider lung transplantation for COVID-19 | Lancet Respiratory Medicine | 32 days | save | | | | |
| Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient | Lancet Respiratory Medicine | 32 days | save | | | | |
| Apples and oranges: international comparisons of COVID-19 observational studies in ICUs | Lancet Respiratory Medicine | 36 days | save | | | | |
| Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial | Lancet Respiratory Medicine | 39 days | save | | | | |
| The EVALI outbreak and vaping in the COVID-19 era | Lancet Respiratory Medicine | 43 days | save | | | | |
| Pollen count data and respiratory diseases in South Africa | Lancet Respiratory Medicine | 44 days | save | | | | |
| Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study | Lancet Respiratory Medicine | 44 days | save | | | | |
| ECMO for severe ARDS associated with COVID-19: now we know we can, but should we? | Lancet Respiratory Medicine | 44 days | save | | | | |
| Hypersensitivity pneumonitis: the first diagnostic guidelines | Lancet Respiratory Medicine | 46 days | save | | | | |
| Living pig bioreactors can repair damaged donor lungs | Lancet Respiratory Medicine | 50 days | save | | | | |
| COVID-19, asthma, and return to school | Lancet Respiratory Medicine | 51 days | save | | | | |
| SARS-CoV-2 viral load predicts COVID-19 mortality | Lancet Respiratory Medicine | 51 days | save | | | | |
| Autopsy insights from the EVALI epidemic | Lancet Respiratory Medicine | 53 days | save | | | | |
| Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series | Lancet Respiratory Medicine | 53 days | save | | | | |
| COVID-19 and preschool wheeze care: lessons learned | Lancet Respiratory Medicine | 53 days | save | | | | |
| COVID-19 interstitial pneumonia: monitoring the clinical course in survivors | Lancet Respiratory Medicine | 54 days | save | | | | |
| Use of facemasks during the COVID-19 pandemic | Lancet Respiratory Medicine | 54 days | save | | | | |
| How COVID-19 could benefit tuberculosis and HIV services in South Africa | Lancet Respiratory Medicine | 54 days | save | | | | |
| | 
report | next » |
| |
